often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher ...

But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...

SEC recommends marketing approval for Dr Reddy's SPMS drug Siponimod tablets: Gireesh Babu, New Delhi Friday, November 8, 2024, 08:00 Hrs [IST] The Subject Expert Committee (SEC), ...

Christina Applegate suffers from multiple sclerosis (MS) - a condition that affects the brain and spinal cord. There are three types of MS and each can manifest in different ways ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

Higher blood levels of bile acids, molecules that aid fat absorption in the gut, are linked to slower MS progression, per ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

Immunic, Inc. ( (IMUX) ) has released its Q3 earnings. Here is a breakdown of the information Immunic, Inc. presented to its investors.

New data suggest the frequency of damage and repair processes correlates with disease severity and disability in multiple ...

In addition to the overall PMS population, the data would also deliver insights on its sub-forms, including non-relapsing secondary progressive MS, a subtype with the highest unmet medical need.

Patients with multiple sclerosis found that their symptoms did not worsen with intake of tolebrutinib, in the GEMINI 1 and 2 studies.